Studies On The Expression Of Muscarinic Receptors: Implications For The Pathology Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$498,791.00
Summary
Schizophrenia is a severe psychiatric disorder that affects approximately 1% of the population. This project will help define changes in the molecules in the brain of subjects with schizophrenia which are likely to be involved in two symptoms of the disorder, the psychoses and cognitive deficits. Understanding the cause of the cognitive deficits of schizophrenia is a high priority because they are the most disabilitating symptom of the disorder and do not respond to current drug treatments.
Clarifying The Pathogenic Role Of Arousal-hyperventilation In Obstructive And Central Sleep Apnoea: Testing Fundamental Pathophysiological Mechanisms And A Strategic New Treatment
Funder
National Health and Medical Research Council
Funding Amount
$414,717.00
Summary
This project is designed to understand the mechanisms underpinning much more stable breathing during deep sleep in obstructive sleep apnoea (OSA). A newly developed analytical technique will be used to examine breathing effort changes across sleep, and interactions with respiratory-induced awakenings in OSA patients. In addition, a new treatment designed to stabilise breathing will be tested and refined towards a new treatment option for OSA and for central sleep apnoea.
Enhancing Erythropoietin Therapy In Ischaemia-reperfusion Injury Of Heart And Kidney
Funder
National Health and Medical Research Council
Funding Amount
$361,021.00
Summary
Heart attacks and kidney disease from a lack of blood flow are common causes of morbidity and have poor treatment options. Erythropoietin (epo) is a useful new treatment, but there remain some caveats to its use in humans: eg. it may cause excessive scarring during repair. Use of epo with an anti-inflammatory drug may decrease scarring and provide benefit to long-term health. We plan to carefully define the biomolecular pathways of injury and repair, to better plan this therapy for human use.